natgillin/translations-raw huggingface dataset:
Use of the antibody of any one of claims 1 to 17 for the manufacture of a medicament for improving the outcome in a mammal undergoing one or more of an orthopedic procedure, dental procedure, implant surgery, joint replacement, bone grafting, bone cosmetic surgery and bone repair such as fracture healing, nonunion healing, delayed union healing and facial reconstruction, wherein the medicament is for administering to said mammal before, during and/or after said procedure, replacement, graft, surgery or repair. 
Monoklonsko protutijelo prema bilo kojem od patentnih zahtjeva 1 do 11, naznačeno time, da je namijenjeno poboljšanju ishoda pri ortopedskim postupcima, stomatološkim zahvatima, operacijama usađivanja, zamjene zgloba, presađivanja kosti, plastične kirurgije kosti ili popravka kosti, kao što su liječenje prijeloma, liječenje nesrastanja, liječenje odgođenog zarastanja ili rekonstrukcije lica.
A mouse cell obtained from the mouse of claim 1 . 
Mišja stanica čiji genom sadrži:
The compound for use of claim 1, wherein the compound is formulated for administration in an amount sufficient to provide a plasma concentration of the compound at steady state at a level higher than the IC90 for PI3K-δ and at a level higher than the IC50 for PI3K-Y. 
Spoj za uporabu prema zahtjevu 1, naznačen time što je spoj formuliran za primjenu u količini koja je dovoljna da osigura koncentraciju spoja u plazmi u stabilnom stanju u razini koja je veća od IC90 za PI3K-δ i u razini koja je veća od IC50 za PI3K-Y.
This means that, unlike other polyols, isomalt exhibits no cooling effect. 
To znači da, za razliku od ostalih pirola, izomalt ne iskazuje učinak hlađenja.
<223> Chimeric Ab comprising sequences from mus musculus and homo sapiens 
Konstrukt kimernog protutijela koji sadrži sljedove iz Mus musculus i <212> DNA
A method according to claim 14, characterised in that said second particulate material comprises a stainless steel slag material which contains less Y-dicalcium silicate than said first particulate material. 
Postupak u skladu s patentnim zahtjevom 14, naznačen time što navedeni drugi partikulirani materijal sadrži troščani materijal iz proizvodnje nehrđajućeg čelika, koji sadrži manje Y-dikalcijevog silikata od navedenog prvog partikuliranog materijala.
WO 96/35628 discloses a composite package for use in storing a laser or optically readable disc. 
WO 96/35628 otkriva složeno pakiranje koje se koristi za pohranjivanje laserskih ili optičkih diskova za pretraživanje.
In a further embodiment are compounds of formula (Ic): in which: R3 is selected from hydrogen and halo; R4 is selected from -SF5 and -Y2-CF2-Y3; R6 when linked to a nitrogen of the pyrazolyl ring is selected from hydrogen, methyl, hydroxy-ethyl, fluoro-ethyl, ethyl and cyclopropyl; and R6 when linked to a carbon atom of the pyrazolyl ring is selected from hydrogen, hydroxy, methyl, methoxy, cyano, trifluoromethyl, hydroxy-methyl, halo, amino, fluoro-ethyl, ethyl and cyclopropyl; R7 is selected from hydroxy, methyl, halo, methoxy, hydroxy-methyl, amino, methyl-amino, amino-methyl, trifluoromethyl, 2-hydroxypropan-2-yl, methyl-carbonyl-amino, dimethyl-amino, 2-amino-3-methylbutanoyl)oxy, carboxy, methoxy-carbonyl, phosphonooxy, cyano and amino-carbonyl; Y1 is selected from CH and N; Y2 is selected from CF2, O and S(O)0-2; Y3 is selected from hydrogen, fluoro, chloro, methyl, difluoromethyl and trifluoromethyl; or the pharmaceutically acceptable salts thereof. 
2. = Spoj prema zahtjevu 1, naznačen time, da ima formulu (Ib): Ra Rg je odabran od vodika i halo; je odabran od -SFs i -Y2-CF2-Y3; kada je povezan na dušik od pirazolil-prstena, tada je odabran od sljedećih: vodik, metil, fluoro-etil, etil i ciklopropil; i Rs kada je povezan na atom ugljika od pirazolil-prstena, tada je odabran od sljedećih: vodik, hidroksi, metil, metoksi, cijano, trifluorometil, hidroksi-metil, halo, amino, fluoro-etil, etil i ciklopropil; je odabran od sljedećih; hidroksi, metil, halo, metoksi, hidroksi-metil, amino, metil-amino, amino-metil, trifluorometil, 2-hidroksipropan-2-il, metil-karbonil-amino, dimetil-amino, 2-amino-3-metilbutanoil)oksi, karboksi, metoksi-karbonil, fosfonooksi, cijano i amino-karbonil; je odabran od CH 1 N; je odabran od CF,, O i S(O)o.; je odabran od sljedećih: vodik, fluoro, kloro, metil, difluorometil i trifluorometil; ili njegove farmaceutski prihvatljive soli.
A1, A2, A3, A4, A5and A6 are independently selected from the group consisting of CR3 and N, provided that at most 3 of A1, A2, A3, A4, A5 and A6 are N; 
, A2, A3, A4, A5 i A6 su neovisno odabrani iz skupine koju čine CR3 i N, uz uvjet da najviše tri od A1, A2, A3, A4, A5 i A6 budu N;
FG1 is an azide group and FG2 is an acetylene group, or wherein FG1 is an acetylene group and FG2 is an azide group; or 
FG1 je azidna skupina, a FG2 je acetilenska skupina ili pri čemu je FG1 acetilenska skupina, a FG2 je azidna skupina; ili
This provided asenapine maleate orthorhombic form (224 g, 86%). 
Ovim je dobiven ortorombski oblik asenapin maleata (224 g, 86%).
A kit of parts comprising (b) an antagonist of M3 muscarinic receptors as defined in claim 1 or 2 together with instructions for simultaneous, concurrent, separate or sequential use in combination with (a) a B2 agonist as defined in any one of claims 1 and 3 to 7 for the treatment of a patient suffering from or susceptible to a respiratory disease as defined in claim 11 or 12. 
Komplet dijelova koji sadrži (b) antagonist M3 muskarinskih receptora kako je definirano u patentnom zahtjevu 1 ili 2 zajedno s uputama za istovremenu, paralelnu, odvojenu ili sekvencijalnu uporabu u kombinaciji s B2 agonistom kako je definirano u zahtjevu 1 ili 3, naznačen time, da je namijenjen za uporabu pri liječenju pacijenata koji pate od ili su podložni bolestima dišnih putova kako je definirano u zahtjevu 7 ili 8.
The peptide antagonist of Kv1.3 of claim 11, comprising the amino acid sequence of SEQ ID NOs: 3 or 42. 
peptidni antagonist Kv1.3 koji sadrži sekvencu aminokiselina SEQ ID NOs: 3-54, 56-83, 85 ili 87-110;
Tanker according to claim 6 or 7, wherein the water resisting construction comprises a flexible seal (34) sealing a gap between the top deck of the tank module and the periphery of the hatch opening. 
Tanker prema zahtjevu 6 ili 7, naznačen time da - vodootporna konstrukcija sadrži savitljivu brtvu (34) koja brtvi prazninu između najgornje palube modularnog spremnika i ruba palubnog otvora.
Compound 11 may be synthesized from Compound 1: 
Postupak dobivanja Spoja 1: O
1 according to the first embodiment (hybrid system including the line through which LNG is compressed by the high pressure pump 120 and supplied as fuel to the propulsion system, and the line through which BOG is compressed by the compressor 150 and supplied as fuel to the propulsion system) and the liquefied gas treatment system illustrated in FIG. 2 according to the second embodiment. According to embodiments of the present invention, it is obvious that the liquefied gas treatment systems illustrated in FIGS. 
Sustav za obradu ukapljenog plina u skladu s patentnim zahtjevom 1, naznačen time što kompresor uključuje prvi kompresor (13a) i drugi kompresor (13b), gdje se prva struja se grana u drugu struju i treću struju nakon prolaska kroz prvi kompresor. Sustav za obradu ukapljenog plina u skladu s patentnim zahtjevom 7, naznačen time što se treću struju dodatno komprimira u drugom kompresoru (13b) i šalje u izmjenjivač topline (21).
The invention is directed to a process for the production of urea from ammonia and carbon dioxide in a urea plant containing a synthesis section comprising two reactor sections, a stripper and a condenser, and a recovery section, wherein in the first reactor section a first synthesis solution is formed that is fed to the second reactor section; fresh carbon dioxide is fed to the second reactor section and in the second reactor section a second synthesis solution is formed that is fed to the stripper, wherein the second synthesis solution is stripped with the use of carbon dioxide as stripping gas and the mixed gas stream obtained in the stripper is sent to the condenser together with fresh ammonia and a carbamate stream, whereafter the condensate that is formed in the condenser is fed to the first reactor section and the urea stream that is obtained in the stripper is further purified in a recovery section. 
HR P20171925 T1 PATENTNI ZAHTJEVI no Postupak za proizvodnju uree od amonijaka i ugljičnog dioksida u postrojenju za proizvodnju uree, a) pri čemu postrojenje za proizvodnju uree sadrži odjeljak za regeneraciju i sekciju za sintezu visokog tlaka koja obuhvaća dva reaktorska odjeljka, ekstrahator i kondenzator, b) pri čemu se u prvom reaktorskom odjeljku stvara prva otopina sinteze koja se dovodi u drugi reaktorski odjeljak; c) svježi ugljični dioksid se dovodi u drugi reaktorski odjeljak i u drugom reaktorskom odjeljku se stvara se druga otopina sinteze koja se dovodi u ekstrahator, d) pri tome se druga otopina sinteze uklanja uporabom ugljičnog dioksida kao plina za uklanjanje, i tok miješanog plina dobiven u ekstrahatoru šalje se kondenzatoru zajedno sa svježim amonijakom i strujom karbamata i kondenzira pod uklanjanjem topline, e) = zatim se kondenzat koji se stvara u kondenzatoru dovodi u prvi reaktorski odjeljak f)
applying and distributing on a floor the composition in a dosage of 4-12 litres per m2. The method according to claim 10, wherein the dosage of the composition is 4-8 litres per m2. 
Sastav za korištenje prema zahtjevu 6, naznačen time da se sastav nanosi 1 raspodijeli na podu u dozi od 4 - 12 litara na m2, poželjno 4 - 8 litara na m2.
a polymerisation initiator selected from peroxy-group containing compounds and azo-group containing compounds (e.g. 
inicijator polimerizacije odabran od spojeva koji sadrže peroksi-skupinu i spojeva koji sadrže azo-skupinu (npr.
wherein x2 is a basic amino acid. The cyclic peptide according to claim 15, wherein at least one of the aliphatic amino acid residues except Cys is replaced by a different aliphatic amino acid except Cys. 
Ciklički peptid u skladu s patentnim zahtjevom 13 ili 14, naznačen time što je najmanja jedna od bazičnih aminokiselina zamijenjena drugačijom aminokiselinom koju se bira iz skupine koju čine bazične aminokiseline.
Use of a compound according to any one of Claims 1 to 21 for the manufacture of a medicament for use in the improvement of cognitive function and memory impairment, including the treatment of diseases selected from dementia, Alzheimer's disease, short term memory loss and attention deficit disorders; neurodegenerative disorders, Parkinson's Disease, cerebral apoplexy and craniocerebral trauma; hypotension, hemorrhagic and endotoxin-induced hypotension; Parkinson's disease; Huntington's disease; Pick's disease; Creutzfeld-Jakob disease; head trauma; and age-related cognitive decline. 
Primjena spoja prema bilo kojem od Zahtjeva od 1 do 21, naznačena time, da je za proizvodnju lijeka koji se upotrebljava za poboljšanje kognitivne funkcije te kod slabljenja memorije, što uključuje liječenje bolesti koje su odabrane od demencije, Alzheimerove bolesti, kratkotrajnog gubitka pamćenja i poremećaja smanjene koncentracije, neurodegenerativnih bolesti, Parkinsonove bolesti, cerebralne apopleksije i kraniocerebralne traume, hipotenzije, hemoragije i hipotenzije uzrokovane endotoksinom, Parkinsonove bolesti, Huntingtonove bolesti, Pikove bolesti, Creutzfeld-Jakobove bolesti, traume glave i kognitivnog opadanja koje je povezano sa godinama.
For example, the inhalable form of the medicament may be an aerosol comprising a mixture of (A) and (B) in solution or dispersion in a, propellant, or a combination of an aerosol containing (A) in solution or dispersion in a propellant with an aerosol containing (B) in solution or dispersion in a propellant. 
Na primjer, oblik lijeka koji se može inhalirati, može biti aerosol koji sadrži smjesu (A) i (B) u otopini ili disperziji u propelantu, ili kombinacija aerosola koji sadrži (A) u otopini ili disperziji u propelantu s aerosolom koji sadrži (B) u otopini ili disperziji u propelantu.
The tablet according to any of the above claims, wherein the tablet has an acid neutralizing capacity of about 13 mEq to about 18 mEq. 
Tableta prema bilo kojem od gore navedenih zahtjeva, naznačena time da tableta ima kiseli neutralizacijski kapacitet od oko 13 mEq do oko 18 mEq.
siRNA for use according to a preceding claim wherein said siRNA is administered topically to the eye. 
7. < siRNK za primjenu prema prethodnom patentnom zahtjevu gdje spomenuta siRNK je administrirana lokalno na oko.
An “analgesically effective” amount of an analgesic agent means an amount of agent capable of lowering the level of pain experienced by a patient. 
"Analgetički učinkovita" količina analgetičkog sredstva označuje količinu sredstva koja je sposobna sniziti razinu boli koju trpi pacijent.
at least about 20% (by wt) or at least about 30 % (by wt) or at least about 50 % (by wt) of polyethylene oxide having, based on rheological measurements, a molecular weight of at least 1,000,000. 
Postupak prema zahtjevu 29, naznačen time da se barem oko 20%, barem oko 40% ili barem oko 75% polietilen oksida visoke molekulske mase rastopi.
The system of claim 1, wherein the plurality of cold-box compartments comprises a pair of compartments. The system of claim 1, wherein a first one of the plurality of compartments is mounted above a second one of said plurality of compartments. The system of claim 1, wherein each one of the plurality of cold-box compartments comprises at least one hatch for access to an interior of each of said compartments. 
Uređaj u skladu s patentnim zahtjevom 6, naznačen time, da je otvor (20, 22; 222) predviđen za pristup unutrašnjosti svakog od navedenih odjeljaka za rashladni uređaj (12, 14; 112, 114; 212, 214). Uređaj u skladu s barem jednim od patentnih zahtjeva 1 do 7, naznačen time, da spremnik za tekući plin sadržava plin koji sadržava tekući prirodni plin (LNG).
A radio communication terminal apparatus (100) for possible use in Coordinated Multiple Point transmission and reception, CoMP, the terminal apparatus comprising: 
HR P20181417 T1 PATENTNI ZAHTJEVI 1. Radio komunikacijski terminalni uređaj (100) za moguću uporabu u Koordiniranom prijenosu i prijemu Više
represents a hydrogen atom or a C1-6 alkyl group; represents a hydrogen atom, a C1-6 alkoxy carbonyl group or a C1-6 alkyl group optionally substituted by 1 to 4 substituents selected from a halogen atom, a phenyl group, a hydroxyl group or a C1-6 alkoxy group; 
R4 predstavlja atom vodika ili C,.4 alkilnu skupinu; R5 predstavlja atom vodika, C,.4 alkilnu skupinu, izborno supstituiranu s 1 do 4 supstituenta, koje se bira između atoma halogena, fenilne skupine, hidroksilne skupine ili C,.s alkoksi skupine;
The compound of claim 6, wherein the compound is represented by the following structural formula: 
Spoj prema zahtjevu 19, pri čemu je spoj prikazan slijedećom strukturnom formulom: a
Ivabradine hydrochloride Form IV according to any of claims 1 to 4 or the pharmaceutical composition according to claims 12 to 13, for use in therapy, preferably for use in the treatment of bradycardics, myocardial ischaemia, supraventricular rhythm disturbances, chronic stable angina pectoris in coronary artery disease adults with normal sinus rhythm, myocardial infarct, heart failure and associated rhythm disturbances. 
Ivabradin-hidroklorid, Oblik IV, u skladu s patentnim zahtjevima 1 do 5 ili farmaceutski pripravak u skladu s patentnim zahtjevima 9 do 11, naznačeni time što su namijenjeni upotrebi u liječenju bradikardije, ishemije miokarda, supraventrikularnih poremećaja ritma, kronične stabilne angine pektoris kod odraslih osoba s bolešću koronarnih arterija i normalnim sinusnim ritmom, infarkta miokarda, srčane insuficijencije i s njom povezanih poremećaja ritma.
To this end, one subject of the invention is a process for producing polyhydroxyalkanoates or PHA from volatile fatty acid (VFA) molecules, referred to as precursors, produced by anaerobic fermentation from fermentable biomass, characterized in that it comprises at least the following steps: 
HR P20190577 T1 PATENTNI ZAHTJEVI Postupak proizvodnje polihidroksialkanoata ili PHA iz molekula hlapivih masnih kiselina (VFA), zvanih prekursori, proizvedenih anaerobnom fermentacijom iz biomase koja se može fermentirati, naznačeno time da sadrži barem sljedeće korake:
A pharmaceutical composition comprising a compound according to any one of claims 1 to 61 and a second pharmaceutically active agent selected from the group consisting of aspirin, angiotensin II receptor antagonists, calcium channel blockers, beta-blockers, CI1027, CCR5 receptor antagonists, imidazolines, sGCa's (soluble guanylate cyclase activators) antihypertensive agents, diuretics, alpha adrenergic antagonists, ACE (angiotensin converting enzyme) inhibitors, aldosterone receptor antagonists, neutral endopeptidase inhibitors, antidiabetic agents, sulfonylureas, glitazones, cholesterol lowering agents, and alpha-2-delta ligands. 
Farmaceutski pripravak, naznačen time što sadrži spoj u skladu s bilo kojim od patentnih zahtjeva 1 do 61 i dodatno farmaceutski aktivno sredstvo, koje se bira iz skupine koju čine aspirin, antagonisti receptora angiotenzina II, blokatori kalcijskih kalnala, B-blokatori, CI1027, antagonisti receptora CCR5, imidazolini, antihipertenzivna sredstva tipa sGCa (topivi aktivatori gvanilat-ciklaze), diuretici, a-adrenergički antagonisti, inhibitori ACE (angiotenzin-konvertirajući enzim), antagonisti aldosteronskog receptora, inhibitori neutralne endopeptidaze, antidijabetička sredstva, sulfoniluree, glitazoni, sredstva za snižavanje razine kolesterola i a-2-δ ligandi.
which further comprises at least one stabilizer, which is lyophilized, or which comprises one or more anti-IL-6 antibodies comprising (a) a VH chain having the amino acid sequence of SEQ ID NO: 3, 18, or 19; and (b) a VL chain having the amino acid sequence of SEQ ID NO: 2 or 20. 
Farmaceutski ili dijagnostički sastav iz patentnog zahtjeva 7, a) koji nadalje sadrži najmanje jedan stabilizator, b) koji je liofiliziran, ili c) koji sadrži jedno ili više anti-IL-6 protutijela koja sadrže (a) Vg lanac koji ima aminokiselinski slijed SEQ ID NO:3, 18 ili 19; 1 (b) VL lanac koji ima aminokiselinski slijed SEQ ID NO:2 1li 20.
Figures 4 and 5 are schematic illustrations of an atomiser 11 according to the invention which comprises the microfluidic arrangements or nozzle arrangement 1 according to the first or second embodiment for atomising a fluid 12, particularly a highly effective drug or the like, in its untensioned state (Figure 4) and in its tensioned state (Figure 5). 
HR P20060435 T3 Slike 4 i 5 prikazuju shematski atomizer 11 prema izumu koji obuhvaća mikrofluidne naprave ili napravu s mlaznicom 1 prema prvoj ili drugoj izvedbi za atomizaciju tekućine 12, posebno lijeka visoke učinkovitosti ili sličnog, u njegovom nenapregnutom stanju (slika 4) i u njegovom napregnutom stanju (slika 5).
The sanitary set according to claim 2, wherein at least one rolling joint of the set is constructed as a general rolling surface or a section thereof. 
Sanitarni komplet sukladno patentnom zahtjevu 1 ili 2 naznačen time što je najmanje jedan valjkasti spoj tog kompleta napravljen kao opća valjkasta površina (10) ili dio takve površine.
A preferred activated carbon for such a fuel element is PCB-G, and a preferred non-activated carbon is PXC, both available from Calgon Carbon Corporation, Pittsburgh, PA. 
Poželjan aktiviran ugljik za takav gorivi element je PCB-G, poželjan ncaktiviran ugljik je PXC, oba pristupačni od Calgon Carbon Corporation, Pittsburgh, PA.
17: Direct binding ELISA of H28L16 to recombinant full-length human Nogo-A splice (GST-Nogo-A- Biocat 113015). 
Slika 15: ELISA uz izravno vezanje H25L16 na rekombinantni ljudski nadovezak Nogo-A pune duljine (GST-Nogo-A Biocat 113015).
In a preferred embodiment, the alpha adrenergic receptor agonist may be an alpha-1 or alpha-2 adrenergic receptor agonist. 
Kompozicija topičkog gela prema zahtjevu 3, pri čemu agonist alfa adrenergijskog receptora je agonist alfa-1 ili alfa-2 adrenergijskog receptora.
A modified serpin according to any one of clauses 94 to 98 or 101 to 104 comprising the amino acid sequence of residues 25-418 of SEQ ID NO: 12. 
(1i) aminokiselinsku sekvencu ostataka 25-418 od SEQ ID NO: 12 s mutacijom od € do S na ostatku 256;
D-Cyclohexylglycine ethyl ester was prepared from D-cyclohexylglycine, 500 mg (3.1 mmol), by suspending the acid in 15 mL ethanol, adding chlorotrimethylsilane, 2.02 mL (5 equivalents), and heating the mixture at 50° C. for 18 hours. 
D-cikloheksilglicin etil ester pripravljen je iz D-cikloheksilglicina, 500 mg (3.1 mmol), suspendiranjem kiseline u 15 ml etanola, dodavanjem klorotrimetil silana, 2.02 ml (5 ekvivallenata), 1 zagrijavanjem kod 50%C 18 sati.
wherein said ligand binds to the anti-ligand consisting in the amino acid sequence defined by SEQ ID No.20 or SEQ ID No. 
naznačen time da se navedeni ligand veže na anti-ligand koji se nalazi u sekvenci amino kiseline definiranoj sa SEQ ID No.20 ili SEQ ID No.
a C1-6 alkyl group optionally having one 3- to 8-membered monocyclic nonaromatic heterocyclic group optionally having 1 to 3 C1-6 alkyl groups, or 
C1-6 alkil-skupina koja opcijski ima jednu 3-članu do 8-članu monocikličku nearomatsku heterocikličku skupinu koja opcijski ima jednu do tri C1-6 alkil-skupine, ili
Use of a composition containing at least 0.5% by weight, preferably at least 1.0%, by weight of dry matter, of N-heterocyclic substances as an additive in beverages or foodstuffs to prevent or reduce light induced flavour changes in said beverages or foodstuffs, wherein said composition, if it contains caramelised material, exhibits an absorption ratio A280/560 of at least 80, preferably of at least 250. 
Upotreba pripravka koji sadržava najmanje 0,5% po masi, poželjno najmanje 1,0%, po masi suhe tvari, N-heterocikličkih tvari, naznačena time, što se upotrebljava kao aditiv u pićima ili prehrambenim proizvodima za sprečavanje ili smanjivanje promjena arome induciranih svjetlom u spomenutim pićima ili prehrambenim proizvodima, pritom spomenuti pripravak, ako sadržava karamelizirani materijal, pokazuje apsorpcijski omjer A280/550 Od najmanje 80, poželjno od najmanje 250.
4 f and FIG. 4 g present the cut-outs of the inner front wall of the box with the adjoining walls in a variety of versions. 
SI. 4, SI. 4a, SI. 4b i SL 4c prikazuju nekoliko verzija modela unutarnjeg prednjeg zida kutije sa zidovima koji graniče.
The modified FIX polypeptide is useful for treating coagulopathies (congenital or acquired), haematological diseases (congenital or acquired), haemorrhagic disorders (such as haemorrhagic gastritis and/or uterine bleeding), other cardiovascular diseases 
Polipeptid za uporabu, sukladno bilo kojem od zahtjeva 1-3, naznačen fime, da se navedeni polipeptid upotrebljava u liječenju kongenitalne ili stečene koagulopatije, urođene ili stečene hematološke bolesti, hemoragijskog poremećaja ili drugih kardiovaskularnih bolesti.
A compound according to claim 1, or a salt thereof, wherein: 
Paraziticidni sastav prema zahtjevu 1, naznačen time, da PjeN;
The compound of claim 1, with the proviso that compounds and or a pharmaceutically acceptable salt thereof are excluded. 
Spoj ili njegova farmaceutski prihvatljiva sol sukladno zahtjevu 1, gdje je spoj:
The present invention may contain up to 90% of monohydric alcohol(s). 
Ovaj izum može sadržavati do 90 % monohidratnog(ih) alkohola.
The crystalline dihydrogenphosphate salt monohydrate is obtained by crystallization from an aqueous C1-C5 alkanol solution of the dihydrogenphosphate salt as described below. 
Kristalni monohidrat dihidrogenfosfatne soli dobiva se kristalizacijom iz vodene C;-Cs alkanol otopine dihidrogenfosfatne soli, kako je dolje opisano.
Assembly according to claim 7, wherein a connection piece (28, 39) is provided on the connection surfaces (12, 12') of at least two rotationally symmetric views of each structural member (10, 30, 40, 40'). 
Sklop u skladu s patentnim zahtjevom 7, naznačen time, da je na spojnim površinama (12, 12 ') predviđen spojni dio (28, 39) od najmanje dva rotacijsko simetrična prikaza svakog konstrukcijskog elementa (10, 30, 40, 40).